Cytokinetics has signed an agreement to sell a portion of the potential royalty from Amgen on worldwide sales of omecamtiv mecarbil to Royalty Pharma.

Omecamtiv mecarbil is a novel cardiac myosin activator that accelerates the rate-limiting step of the myosin enzymatic cycle and shifts the enzymatic cycle in favour of the force-producing state.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Amgen and Cytokinetics collaborated in 2006 to discover, develop, and commercialise small molecule therapeutics designed to activate cardiac muscle to treat heart failure.

The company will also exercise its option to co-invest $40m with Amgen in the Phase III development programme of omecamtiv mecarbil.

Following this, Cytokinetics will receive an incremental royalty of up to 4% on increasing sales of omecamtiv outside of Japan.

“As part of the agreement, Cytokinetics sold a 4.5% royalty on potential worldwide sales of omecamtiv mecarbil to Royalty Pharma for $90m.”

Cytokinetics president and CEO Robert Blum said: “These key corporate developments underscore our steadfast commitment to the promise of omecamtiv mecarbil for the potential treatment of patients with heart failure, and the prudent advancement of our strategy towards commercialisation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are pleased to align with Royalty Pharma on our shared vision of the significant value of omecamtiv mecarbil and how we may realise that upside under our collaboration agreement with Amgen.”

As part of the agreement, Cytokinetics sold a 4.5% royalty on potential worldwide sales of omecamtiv mecarbil to Royalty Pharma for $90m.

Under certain circumstances, the royalty rate purchased is expected to increase up to an additional 1%.

After completing the transaction with Royalty Pharma, Cytokinetics will retain the right to receive more than $600m, as well as double-digit royalties that may be more than 20% on tiered worldwide sales of omecamtiv mecarbil.